<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03671928</url>
  </required_header>
  <id_info>
    <org_study_id>18-AOI-12</org_study_id>
    <nct_id>NCT03671928</nct_id>
  </id_info>
  <brief_title>Study of Circulating Levels of Glicentin</brief_title>
  <acronym>GLICENTINEDIGE</acronym>
  <official_title>Study of Circulating Glicentin Levels in Patients With Intestinal Ischemia</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Centre Hospitalier Universitaire de Nice</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Centre Hospitalier Universitaire de Nice</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Hormones derived from proglucagon represent a family of peptides produced by the alpha cells&#xD;
      of the pancreas and by the intestinal L cells. In the pancreas, the maturation of proglucagon&#xD;
      mainly leads to the synthesis of glucagon, while in the intestine, the cleavage of&#xD;
      proglucagon allows the synthesis of different peptides including glicentine, oxyntomodulin,&#xD;
      Glucagon Like Peptide-1 (GLP-1) and Glucagon Like Peptide-2 (GLP-2).&#xD;
&#xD;
      Glicentin is produced by L cells throughout the digestive tract, from the small intestine to&#xD;
      the rectum, with a majority secretion in the colon. Studies in humans and animals have shown&#xD;
      its role in the intestinal mucosa. It has a stimulating effect on the proliferation of the&#xD;
      intestinal mucosa as well as an effect on smooth muscle cells and regulates trophicity and&#xD;
      intestinal motility. Its circulating rate could be modified in case of intestinal ischemia.&#xD;
      Mesenteric ischemia is a major diagnostic problem with high morbidity and mortality,&#xD;
      particularly in the event of delayed treatment.&#xD;
&#xD;
      The sensitivity and specificity of current markers are low. The identification of new&#xD;
      biomarkers of the disease would improve the diagnosis and management of patients with the&#xD;
      disease.&#xD;
&#xD;
      The objective of the project is to determine a difference in circulating glicentin levels in&#xD;
      patients with intestinal ischemia versus a control group.&#xD;
&#xD;
      On this prospective monocentric study, 40 patients with digestive ischemia will be included&#xD;
      in the Emergency Department of the University Hospital of Nice. A control group of 40&#xD;
      patients with abdominal pain will be formed. The circulating glicentin levels will be&#xD;
      measured on serum by Elisa technique at the Biochemistry Laboratory of the University&#xD;
      Hospital of Nice, work that has been published in 3 scientific journals allowing us to&#xD;
      develop and validate the technique.The staff will determine whether patients with digestive&#xD;
      ischemia have impaired serum glicentin levels.&#xD;
&#xD;
      The evaluation of the interest of new biological markers of mesenteric ischemia such as&#xD;
      glicentine would constitute a definite diagnostic advance. This project could eventually&#xD;
      offer new diagnostic and/or therapeutic perspectives in the management of these patients.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Not yet recruiting</last_known_status>
  <start_date type="Anticipated">January 15, 2019</start_date>
  <completion_date type="Anticipated">January 15, 2021</completion_date>
  <primary_completion_date type="Anticipated">January 15, 2021</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>difference of at least 20% of the serum glicentin dosage in the &quot;intestinal ischemia&quot; group versus the &quot;control&quot; volunteers.</measure>
    <time_frame>24 months</time_frame>
    <description>glicentine dosage</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">80</enrollment>
  <condition>Ischemia Bowel</condition>
  <arm_group>
    <arm_group_label>bowel ischemia</arm_group_label>
    <arm_group_type>Other</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>non-digestive abdominal pain</arm_group_label>
    <arm_group_type>Other</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>additional blood tube</intervention_name>
    <description>sampling of an additional tube at the usual blood test to determine the glicentin level</description>
    <arm_group_label>bowel ischemia</arm_group_label>
    <arm_group_label>non-digestive abdominal pain</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>additional blood sample</intervention_name>
    <description>for le group control, another blood sample is taken outside the usual care.</description>
    <arm_group_label>non-digestive abdominal pain</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  For patients with intestinal ischemia&#xD;
&#xD;
          -  The combination of abdominal pain, altered general condition with abdominal defence&#xD;
             and venous or arterial hyperlactatemia will be signs suggestive of a diagnosis of&#xD;
             digestive ischemia.&#xD;
&#xD;
          -  Patients suspected of digestive ischemia with the following comorbidities may be&#xD;
             included as clinical suspicion and excluded post-operatively: emboligenic heart&#xD;
             disease, arteriopathy, aortic and/or digestive atheromatosis.&#xD;
&#xD;
          -  Patients with suspected digestive ischemia and functional scanning ileus.&#xD;
&#xD;
          -  Patients with intestinal ischemia proven by CT scan with contrast injection: arterial&#xD;
             abnormality such as dissection of an artery for digestive use, thrombosis or embolism&#xD;
             of an artery for digestive use; intestinal or colonic thickening suggestive of&#xD;
             reversible ischemic suffering of the digestive tract; parietal pneumatosis;&#xD;
             gastrointestinal parietal enhancement abnormality (hypo-density ranges or total&#xD;
             absence of enhancement).&#xD;
&#xD;
        The following pathologies will be taken into account: mesenteric ischemia by embolism or&#xD;
        thrombosis.&#xD;
&#xD;
          -  Age over 18 years old&#xD;
&#xD;
          -  Able to understand the study&#xD;
&#xD;
          -  Affiliation to a social security system&#xD;
&#xD;
          -  Signing of an informed consent&#xD;
&#xD;
          -  Accept participation in the study (collection of a Non-Opposition)&#xD;
&#xD;
        For the control group&#xD;
&#xD;
          -  Age over 18 years old&#xD;
&#xD;
          -  Able to understand the study&#xD;
&#xD;
          -  Affiliation to a social security system&#xD;
&#xD;
          -  Signing of an informed consent&#xD;
&#xD;
          -  No personal history of colorectal cancer and obesity&#xD;
&#xD;
          -  Admission to the Emergency Department of the University Hospital of Nice for abdominal&#xD;
             pain with EVA &gt; 3/10 of non-intestinal origin: nephritic colic, hepatobiliary&#xD;
             pathology, gynaecological disease, etc.&#xD;
&#xD;
          -  Abdominal CT excluding digestive tract pathology&#xD;
&#xD;
          -  Accept participation in the study&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  History of bariatric or digestive surgery (stomach, small intestine, colon or rectum)&#xD;
&#xD;
          -  History of chronic inflammatory bowel disease&#xD;
&#xD;
          -  Obese patients (BMI&gt; 30kg/m2)&#xD;
&#xD;
          -  History of type 1 diabetes or insulin treatment&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Damien MASSALOU</last_name>
    <phone>33492038614</phone>
    <email>massalou.d@chu-nice.fr</email>
  </overall_contact>
  <location>
    <facility>
      <name>University Nice Hospital</name>
      <address>
        <city>Nice</city>
        <zip>06000</zip>
        <country>France</country>
      </address>
    </facility>
    <contact>
      <last_name>Damien MASSALOU</last_name>
      <phone>33492038614</phone>
      <email>massalou.d@chu-nice.fr</email>
    </contact>
    <investigator>
      <last_name>Damien MASSALOU</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>September 2018</verification_date>
  <study_first_submitted>September 13, 2018</study_first_submitted>
  <study_first_submitted_qc>September 13, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">September 14, 2018</study_first_posted>
  <last_update_submitted>September 14, 2018</last_update_submitted>
  <last_update_submitted_qc>September 14, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">September 17, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Ischemia</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

